{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-005351","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2024-01-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.181571+00:00","generated_at":"2026-06-06T20:35:00.898826+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Esperion prices $85.1M public offering of 56.7M shares at $1.50; underwriters fully exercise option","bullets":["Offering of 56,700,000 shares priced at $1.50 per share; gross proceeds ~$85.1M.","Underwriters fully exercised option for additional 8,505,000 shares at same price.","Net proceeds expected to be ~$90.8M after underwriting discount and expenses.","Closing expected Jan 23, 2024; Jefferies LLC sole book-running manager.","Proceeds to fund commercialization of NEXLETOL/NEXLIZET, R&D, and working capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-005351","json":"https://secwatch.observer/filing/0001104659-24-005351.json","markdown":"https://secwatch.observer/filing/0001104659-24-005351.md","text":"https://secwatch.observer/filing/0001104659-24-005351.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000110465924005351/0001104659-24-005351-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000110465924005351/tm243774d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T20:35:00.898826+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"194fe6e7cbb42d17764c9523f30552b0641f2d45","claim":"Esperion Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC (effective 2024-01-18).","evidence_excerpt":"On January 18, 2024, Esperion Therapeutics, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Jefferies LLC (“Jefferies”), as representative of the several underwriters listed on Schedule A thereto (the “Underwriters”), related to an underwritten public offering (the “Offering”) of 56,700,000 shares of common stock of the Company, par value $0.001 per share (“Common Stock”), at a purchase price to the public of $1.50 per share.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000110465924005351/0001104659-24-005351-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Jefferies LLC"},{"label":"Effective","value":"2024-01-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}